

Kristian Wachtell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/412127/kristian-wachtell-publications-by-citations.pdf>
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241 papers	12,937 citations	54 h-index	107 g-index
296 ext. papers	14,943 ext. citations	5 avg, IF	5.57 L-index

#	Paper	IF	Citations
241	Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. <i>New England Journal of Medicine</i> , 2008 , 359, 1343-56	59.2	1097
240	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 712-9	15.1	659
239	Prognostic significance of left ventricular mass change during treatment of hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2350-6	27.4	592
238	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. <i>Hypertension</i> , 2005 , 45, 198-202	8.5	436
237	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. <i>Lancet, The</i> , 2016 , 388, 2665-2712	40.2	413
236	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. <i>Circulation</i> , 2004 , 110, 1456-62	16.7	379
235	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Annals of Internal Medicine</i> , 2003 , 139, 901-6	8	376
234	Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2299-307	15.1	306
233	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. <i>Journal of Hypertension</i> , 2002 , 20, 1879-86	1.9	271
232	Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. <i>Circulation</i> , 2011 , 123, 887-95	16.7	242
231	Short- and long-term cause of death in patients treated with primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2101-8	15.1	221
230	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 705-11	15.1	221
229	Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. <i>Hypertension</i> , 2000 , 35, 6-12	8.5	200
228	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. <i>European Heart Journal</i> , 2010 , 31, 883-91	9.5	195
227	Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 1242-8	27.4	187
226	Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. <i>Hypertension</i> , 2002 , 39, 739-43	8.5	176
225	Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. <i>Hypertension</i> , 2007 , 49, 311-6	8.5	168

224	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. <i>Circulation</i> , 2007 , 116, 700-5	16.7	163
223	Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. <i>JACC: Cardiovascular Imaging</i> , 2009 , 2, 390-9	8.4	162
222	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. <i>Circulation</i> , 2002 , 105, 1071-6	16.7	154
221	N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. <i>Hypertension</i> , 2005 , 46, 660-6	8.5	140
220	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. <i>American Journal of Cardiology</i> , 2000 , 85, 466-72	3	140
219	Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. <i>American Journal of Cardiology</i> , 2007 , 99, 970-3	3	125
218	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , 2002 , 20, 405-12	1.9	123
217	Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). <i>European Journal of Echocardiography</i> , 2008 , 9, 809-15		116
216	N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. <i>European Heart Journal</i> , 2007 , 28, 1374-81	9.5	109
215	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. <i>American Heart Journal</i> , 2002 , 143, 319-26	4.9	107
214	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021 , 397, 1625-1636	40	101
213	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. <i>Journal of Hypertension</i> , 2004 , 22, 1805-11	1.9	99
212	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. <i>Blood Pressure</i> , 2001 , 10, 74-82	1.7	97
211	Prognostic value of energy loss index in asymptomatic aortic stenosis. <i>Circulation</i> , 2013 , 127, 1149-56	16.7	91
210	Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. <i>Resuscitation</i> , 2013 , 84, 162-7	4	89
209	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , 2020 , 142, 621-642	16.7	88
208	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. <i>Diabetes Care</i> , 2006 , 29, 595-600	14.6	88
207	Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. <i>American Heart Journal</i> , 1999 , 137, 1062-9	4.9	87

206	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. <i>Journal of Hypertension</i> , 2001 , 19, 1883-91	1.9	86
205	Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. <i>American Heart Journal</i> , 2019 , 214, 60-68	4.9	82
204	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. <i>Hypertension</i> , 2005 , 45, 46-52	8.5	80
203	Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. <i>Hypertension</i> , 2008 , 51, 1109-14	8.5	79
202	Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). <i>American Journal of Cardiology</i> , 2005 , 95, 132-6	3	79
201	Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy. <i>JACC: Cardiovascular Imaging</i> , 2010 , 3, 555-62	8.4	78
200	Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. <i>Lancet, The</i> , 2003 , 362, 619-20	4.0	77
199	Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. <i>Circulation: Cardiovascular Imaging</i> , 2014 , 7, 422-9	3.9	71
198	Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. <i>Circulation</i> , 2002 , 106, 227-32	16.7	70
197	suPAR: A New Biomarker for Cardiovascular Disease?. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1293-303	3.8	67
196	N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. <i>Journal of Hypertension</i> , 2004 , 22, 1597-604	1.9	66
195	Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. <i>Journal of Hypertension</i> , 2003 , 21, 781-7	1.9	65
194	Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. <i>American Journal of Cardiology</i> , 2001 , 87, 54-60	3	65
193	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. <i>Journal of Hypertension</i> , 2002 , 20, 1445-50	1.9	63
192	Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. <i>Journal of Hypertension</i> , 2006 , 24, 775-81	1.9	62
191	Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. <i>Journal of Hypertension</i> , 2000 , 18, 1129-38	1.9	60
190	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. <i>American Heart Journal</i> , 2001 , 141, 784-91	4.9	60
189	Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy). <i>American Journal of Cardiology</i> , 2008 , 101, 510-5	3	58

188	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. <i>American Heart Journal</i> , 2002 , 144, 1057-64	4.9	57
187	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). <i>American Journal of Cardiology</i> , 2002 , 89, 337-41	3	53
186	Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. <i>Hypertension</i> , 2012 , 60, 347-53	8.5	50
185	Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. <i>Hypertension</i> , 2015 , 66, 368-73	8.5	49
184	Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. <i>Journal of Human Hypertension</i> , 2004 , 18, 453-9	2.6	49
183	Heart rate versus heart rate variability in risk prediction after myocardial infarction. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 168-73	2.7	49
182	Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. <i>American Journal of Cardiology</i> , 2010 , 105, 1802-8	3	48
181	Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. <i>Circulation</i> , 2012 , 125, 346-53	16.7	47
180	Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. <i>Blood Pressure</i> , 2005 , 14, 177-83	1.7	47
179	N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis. <i>European Journal of Heart Failure</i> , 2004 , 6, 313-7	12.3	47
178	Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008 , 1, 337-43	6.4	46
177	QT dynamics in risk stratification after myocardial infarction. <i>Heart Rhythm</i> , 2005 , 2, 357-64	6.7	46
176	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. <i>Journal of Hypertension</i> , 2005 , 23, 891-8	1.9	46
175	In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. <i>Blood Pressure</i> , 2010 , 19, 169-75	1.7	45
174	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. <i>Journal of Hypertension</i> , 2012 , 30, 1928-36	1.9	45
173	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. <i>American Heart Journal</i> , 2002 , 144, 530-7	4.9	45
172	Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013 , 6, 243-51	6.4	44
171	Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). <i>Journal of Hypertension</i> , 2010 , 28, 377-83	1.9	44

170	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. <i>Journal of Human Hypertension</i> , 2007 , 21, 625-32	2.6	43
169	New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. <i>Journal of the American Heart Association</i> , 2014 , 3, e000382	6	42
168	Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study. <i>Journal of Hypertension</i> , 2001 , 19, 127-34	1.9	41
167	Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. <i>Heart</i> , 2014 , 100, 28-33	5.1	40
166	Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study). <i>American Journal of Cardiology</i> , 2008 , 101, 1030-4	3	40
165	Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. <i>Journal of Human Hypertension</i> , 2004 , 18, 403-9	2.6	40
164	Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. <i>Journal of Hypertension</i> , 2015 , 33, 2422-30	1.9	35
163	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. <i>Circulation</i> , 2005 , 111, 1924-31	16.7	34
162	Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. <i>International Journal of Cardiology</i> , 2013 , 166, 72-6	3.2	33
161	Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF. <i>Heart</i> , 2014 , 100, 1946-53	5.1	33
160	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. <i>Journal of Hypertension</i> , 2010 , 28, 1541-6	1.9	33
159	Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. <i>Hypertension</i> , 2003 , 41, 75-82	8.5	33
158	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. <i>Journal of Hypertension</i> , 2008 , 26, 26-34	1.9	32
157	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. <i>Journal of Hypertension</i> , 2006 , 24, 655-61	1.9	32
156	Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. <i>American Journal of Cardiology</i> , 2005 , 96, 1692-8	3	32
155	Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). <i>American Journal of Cardiology</i> , 2010 , 106, 999-1005	3.1	31
154	Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. <i>Journal of Human Hypertension</i> , 2004 , 18, 445-52	2.6	31
153	Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. <i>Journal of Hypertension</i> , 2005 , 23, 1083-90	1.9	31

152	Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. <i>Journal of Human Hypertension</i> , 2005 , 19, 301-7	2.6	31
151	Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1142-9	15.1	30
150	A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. <i>Journal of Human Hypertension</i> , 2002 , 16, 591-5	2.6	30
149	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. <i>American Heart Journal</i> , 2003 , 145, 919-25	4.9	30
148	Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial. <i>Current Cardiology Reports</i> , 2016 , 18, 11	4.2	29
147	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. <i>Journal of Hypertension</i> , 2009 , 27, 2351-7	1.9	29
146	Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. <i>PLoS ONE</i> , 2015 , 10, e0128987	3.7	29
145	Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). <i>Blood Pressure</i> , 2010 , 19, 140-4	1.7	27
144	Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). <i>American Journal of Cardiology</i> , 2010 , 106, 1634-9	3	27
143	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. <i>Journal of Hypertension</i> , 2006 , 24, 1531-9	1.9	27
142	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021 , 398, 1053-1064	4.0	27
141	Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study. <i>International Journal of Cardiology</i> , 2013 , 168, 2322-7	3.2	26
140	Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009 , 19, 634-40	4.5	26
139	Overweight, adipocytokines and hypertension: a prospective population-based study. <i>Journal of Hypertension</i> , 2014 , 32, 1488-94; discussion 1494	1.9	25
138	Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, 122-9	4.5	25
137	Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. <i>Hypertension</i> , 2005 , 46, 492-9	8.5	25
136	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2020 , 75, 23-32	8.5	25
135	Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. <i>International Journal of Cardiology</i> , 2014 , 175, 492-8	3.2	24

134	Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. <i>American Journal of Hypertension</i> , 2010 , 23, 845-51	2.3	24
133	Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. <i>Journal of Hypertension</i> , 2000 , 18, 75-81	1.9	24
132	Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS). <i>Circulation</i> , 2016 , 134, 455-68	16.7	24
131	Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. <i>American Journal of Hypertension</i> , 2012 , 25, 1101-9	2.3	23
130	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. <i>Journal of Hypertension</i> , 2008 , 26, 1244-9	1.9	23
129	Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. <i>American Journal of Hypertension</i> , 2005 , 18, 1430-6	2.3	23
128	Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). <i>Blood Pressure</i> , 2014 , 23, 206-12	1.7	22
127	The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 624-30	3.2	22
126	Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data). <i>American Journal of Cardiology</i> , 2011 , 108, 541-7	3	22
125	Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009 , 19, 306-12	4.5	22
124	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. <i>Journal of Hypertension</i> , 2009 , 27, 1165-71	1.9	22
123	Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. <i>Journal of Human Hypertension</i> , 2004 , 18, 411-6	2.6	22
122	Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). <i>American Journal of Cardiology</i> , 2015 , 116, 1840-4	3	21
121	A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis. <i>Heart</i> , 2012 , 98, 377-83	5.1	21
120	Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. <i>American Journal of Hypertension</i> , 2012 , 25, 678-83	2.3	21
119	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. <i>Journal of Hypertension</i> , 2009 , 27, 567-74	1.9	21
118	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). <i>American Journal of Cardiology</i> , 2004 , 94, 1076-80	3	21
117	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. <i>American Heart Journal</i> , 2004 , 148, 538-44	4.9	21

116	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 242-8		20
115	Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty. <i>European Heart Journal</i> , 2007 , 28, 407-14	9.5	20
114	Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. <i>Hypertension</i> , 2015 , 66, 945-53	8.5	19
113	Adjusting parameters of aortic valve stenosis severity by body size. <i>Heart</i> , 2014 , 100, 1024-30	5.1	18
112	Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study. <i>Current Problems in Cardiology</i> , 2013 , 38, 365-409	17.1	18
111	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 434-41	3.9	18
110	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , 2007 , 25, 871-6	1.9	18
109	Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. <i>Journal of Hypertension</i> , 2007 , 25, 1079-85	1.9	18
108	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. <i>Kidney International</i> , 2004 , S56-8	9.9	18
107	Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. <i>Journal of Cardiac Failure</i> , 2002 , 8, 8-14	3.3	18
106	Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). <i>American Journal of Cardiology</i> , 2018 , 121, 739-745	3	17
105	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016 , 203, 697-701	3.2	17
104	Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. <i>Stroke</i> , 2014 , 45, 1939-46	6.7	17
103	Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. <i>American Journal of Hypertension</i> , 2013 , 26, 567-73	2.3	17
102	Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). <i>American Journal of Cardiology</i> , 2009 , 104, 1098-104	3	17
101	Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. <i>Journal of Hypertension</i> , 2010 , 28, 1534-40	1.9	17
100	24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy. <i>Journal of Human Hypertension</i> , 2004 , 18, 391-6	2.6	17
99	Antihypertensive Treatment With β -Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	16

98	Aortic root geometry in aortic stenosis patients (a SEAS substudy). <i>European Journal of Echocardiography</i> , 2011 , 12, 585-90		16
97	Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. <i>American Journal of Hypertension</i> , 2008 , 21, 273-9	2.3	16
96	Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). <i>Journal of Human Hypertension</i> , 2004 , 18, 417-22	2.6	16
95	Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 330-8	3.9	15
94	The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008 , 2, 507-13	3.4	15
93	Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , 2006 , 24, 2079-84	1.9	15
92	Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. <i>Diabetic Medicine</i> , 2005 , 22, 1005-11	3.5	15
91	Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. <i>American Journal of Hypertension</i> , 2001 , 14, 768-74	2.3	15
90	The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. <i>Journal of Atrial Fibrillation</i> , 2013 , 5, 789	0.8	15
89	Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. <i>Journal of Hypertension</i> , 2014 , 32, 667-72	1.9	14
88	Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. <i>Journal of Human Hypertension</i> , 2011 , 25, 178-85	2.6	14
87	Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. <i>Heart Rhythm</i> , 2006 , 3, 660-4	6.7	14
86	Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Human Hypertension</i> , 2004 , 18, 397-402	2.6	14
85	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). <i>American Journal of Cardiology</i> , 2002 , 89, 399-402	3	14
84	Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. <i>Journal of Hypertension</i> , 2013 , 31, 2060-8	1.9	13
83	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , 2008 , 26, 1472-6	1.9	13
82	Maximal exercise capacity is related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. <i>American Journal of Hypertension</i> , 2001 , 14, 1205-10	2.3	13
81	Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. <i>Blood Pressure</i> , 2017 , 26, 150-155	1.7	12

80	Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. <i>American Heart Journal</i> , 2012 , 163, 690-6	4.9	12
79	Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. <i>Blood Pressure</i> , 2012 , 21, 6-11	1.7	12
78	Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy. <i>Journal of Human Hypertension</i> , 2003 , 17, 305-11	2.6	12
77	Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. <i>American Journal of Hypertension</i> , 2002 , 15, 398-404	2.3	12
76	Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population. <i>International Journal of Cardiology</i> , 2015 , 184, 466-472	3.2	11
75	Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. <i>Journal of Hypertension</i> , 2015 , 33, 1480-6	1.9	11
74	In-treatment stroke volume predicts cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2011 , 29, 1508-14	1.9	11
73	Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. <i>American Heart Journal</i> , 2009 , 157, 177-84	4.9	11
72	Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Human Hypertension</i> , 2004 , 18, 431-6	2.6	11
71	Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. <i>Journal of Human Hypertension</i> , 2004 , 18, 423-30	2.6	11
70	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study). <i>PLoS ONE</i> , 2014 , 9, e101522	3.7	10
69	Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin. <i>Journal of Hypertension</i> , 2014 , 32, 2231-7; discussion 2237	1.9	10
68	Left atrial volume as predictor of valve replacement and cardiovascular events in patients with asymptomatic mild to moderate aortic stenosis. <i>Echocardiography</i> , 2013 , 30, 1008-14	1.5	10
67	Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?. <i>Current Vascular Pharmacology</i> , 2010 , 8, 134-9	3.3	10
66	Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. <i>Blood Pressure</i> , 2007 , 16, 392-7	1.7	10
65	Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. <i>American Journal of Hypertension</i> , 2001 , 14, 861-7 ³	2.3	10
64	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). <i>Blood Pressure</i> , 2009 , 18, 180-6	1.7	9
63	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. <i>Hypertension</i> , 2006 , 47, 868-73	8.5	9

62	Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study. <i>International Journal of Cardiology</i> , 2015 , 180, 122-8	3.2	8
61	SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. <i>Open Heart</i> , 2018 , 5, e000743	3	8
60	Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis. <i>American Journal of Cardiology</i> , 2019 , 124, 1736-1740	3	8
59	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. <i>Journal of Human Hypertension</i> , 2009 , 23, 105-12	2.6	8
58	Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Journal of Hypertension</i> , 2008 , 26, 806-12	1.9	8
57	Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. <i>Blood Pressure</i> , 2006 , 15, 198-206	1.7	8
56	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. <i>American Journal of Hypertension</i> , 2003 , 16, 180-6	2.3	8
55	Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. <i>Blood Pressure</i> , 2002 , 11, 285-92	1.7	8
54	SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1462-1469	3.8	7
53	Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. <i>American Journal of Hypertension</i> , 2012 , 25, 1017-23	2.3	7
52	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. <i>Journal of Hypertension</i> , 2012 , 30, 513-21	1.9	7
51	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. <i>Journal of Hypertension</i> , 2012 , 30, 1252-9	1.9	7
50	Left ventricular systolic performance in asymptomatic aortic stenosis. <i>Country Review Ukraine</i> , 2008 , 10, E16-E22		7
49	Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension. <i>PLoS ONE</i> , 2015 , 10, e0117864	3.7	7
48	Do ßBlockers Cause Depression?: Systematic Review and Meta-Analysis of Psychiatric Adverse Events During ßBlocker Therapy. <i>Hypertension</i> , 2021 , 77, 1539-1548	8.5	7
47	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 1522-1545	1.9	7
46	SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 355-67	2.5	6
45	Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). <i>American Journal of Cardiology</i> , 2014 , 114, 751-6	3	6

44	High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy. <i>Open Heart</i> , 2015 , 2, e000152	3	6
43	Is it time to change the definition of normal urinary albumin excretion?. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, 650-1		6
42	Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy. <i>Journal of Human Hypertension</i> , 2004 , 18, 437-43	2.6	6
41	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). <i>American Journal of Cardiology</i> , 2005 , 95, 280-3	3	6
40	Acute myocardial infarction and lesion location in the left circumflex artery: importance of coronary artery dominance. <i>EuroIntervention</i> , 2016 , 12, 441-8	3.1	6
39	Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis. <i>Scandinavian Cardiovascular Journal</i> , 2016 , 50, 138-45	2	6
38	Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. <i>Journal of Hypertension</i> , 2014 , 32, 2472-8; discussion 2478	1.9	5
37	Pro-coagulant activity during exercise testing in patients with coronary artery disease. <i>Thrombosis Journal</i> , 2017 , 15, 3	5.6	5
36	Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. <i>American Journal of Hypertension</i> , 2014 , 27, 966-72	2.3	5
35	Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. <i>American Journal of Hypertension</i> , 2008 , 21, 701-7	2.3	5
34	Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 169-73	2.3	5
33	Sudden cardiac death in asymptomatic patients with aortic stenosis. <i>Heart</i> , 2020 , 106, 1646-1650	5.1	5
32	High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease. <i>International Journal of Cardiology</i> , 2019 , 287, 1-6	3.2	4
31	Effect of simvastatin and ezetimibe on suPAR levels and outcomes. <i>Atherosclerosis</i> , 2018 , 272, 129-136	3.1	4
30	Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. <i>Journal of Hypertension</i> , 2011 , 29, 997-1004	1.9	4
29	Does lowering cholesterol have an impact on the progression of aortic stenosis?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008 , 2, 277-86	3.4	4
28	Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. <i>Current Cardiology Reports</i> , 2006 , 8, 356-64	4.2	4
27	Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. <i>Journal of Human Hypertension</i> , 2004 , 18, 375-80	2.6	4

26	Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. <i>Blood Pressure</i> , 2019 , 28, 317-326	1.7	3
25	Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy). <i>American Journal of Cardiology</i> , 2007 , 100, 937-43	3	3
24	Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. <i>American Journal of Hypertension</i> , 2007 , 20, 771-6	2.3	3
23	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. <i>American Journal of Hypertension</i> , 2002 , 15, A15	2.3	3
22	Leisure-time physical inactivity and risk of myocardial infarction and all-cause mortality: a case-control study. <i>International Journal of Cardiology</i> , 2014 , 177, 599-600	3.2	2
21	Prevention of congestive heart failure in high risk patients. <i>European Heart Journal</i> , 2009 , 30, 638-9	9.5	2
20	Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study. <i>Cardiology</i> , 2008 , 109, 163-71	1.6	2
19	Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. <i>Journal of Human Hypertension</i> , 2008 , 22, 634-40	2.6	2
18	Evaluation of Cardiac Damage in Hypertension: Electrocardiography 2015 , 3-12		1
17	Response to Letters Regarding Article, Outcome of Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction <i>Circulation</i> , 2011 , 124,	16.7	1
16	The effect of angiotensin receptor blockers for preventing atrial fibrillation. <i>Current Hypertension Reports</i> , 2007 , 9, 278-83	4.7	1
15	The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. <i>Journal of Human Hypertension</i> , 2006 , 20, 460-4	2.6	1
14	Albuminuria and Mortality in Hypertension. <i>Annals of Internal Medicine</i> , 2004 , 141, 245	8	1
13	On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. <i>Blood Pressure</i> , 2020 , 29, 319-326	1.7	0
12	Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. <i>Exploration of Medicine</i> , 128-138	1.1	0
11	Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 149-159	1.1	0
10	Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.. <i>Reviews in Cardiovascular Medicine</i> , 2022 , 23, 95	3.9	0
9	Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 139-148	1.1	0

8	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 160-172	1.1	O
7	Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. <i>Blood Pressure</i> , 2019 , 28, 84-92	1.7	
6	Global systolic load, left ventricular hypertrophy, and atrial fibrillation. <i>American Heart Journal</i> , 2012 , 164, e13	4.9	
5	Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. <i>Blood Pressure</i> , 2010 , 19, 145-51	1.7	
4	P-212: The effect of losartan versus atenolol on carotid atherosclerosis in the common carotid arteries in hypertension. Icarus, a life substudy. <i>American Journal of Hypertension</i> , 2004 , 17, S111	2.3	
3	The Electrocardiogram as a Risk Predictor in Asymptomatic Aortic Stenosis 2013 , 35-45		
2	Frequency and Impact of Hyponatremia on All-Cause Mortality in Patients With Aortic Stenosis. <i>American Journal of Cardiology</i> , 2021 , 141, 93-97	3	
1	Exercise-induced change in circulating NT-proBNP could not distinguish between patients with and without coronary artery disease: the CADENCE study.. <i>Scandinavian Cardiovascular Journal</i> , 2022 , 56, 107-113	2	